Health Properties of Pecan Nut Consumption
ConditionHealthy Adults
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-75
SponsorUniversity of California, Davis
About this trial
The main goal of this clinical study is to see if consuming pecan nuts will result in improvements in overall body metabolism such as in blood lipids, markers of inflammation, blood pressure, cognitive performance and changes in bacteria living in the gut in adults 45 to 75 years of age.
Participants will take part in two 3-month intervention periods, separated by 4-6 weeks, in random order ( a total of approximately 7 months). During one intervention period, they will include pecan nuts in their diet each day, while during the other intervention period they will avoid pecans in their diet. There will be an initial screening visit to evaluate eligibility and four study visits to the clinic.
Participants will be asked to complete some questionnaires about their diet, physical and cognitive health, and provide blood and stool samples, and have their blood pressure measured.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Design model
Crossover
Treatments tested in this trial
pecan nut
Other interventionDose - 2 ounces of pecan nuts, daily
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: Pecan nut then no nutExperimental treatment 1 intervention
Group B: No nut then pecan nutExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in vascular response at 3 months
Vascular response as measured by Pulse Wave Velocity (PWV)
Time frame
Change from baseline at 3 monthsSecondary outcomes
1
Change in blood lipids over 3 months
Blood lipids as measured by clinical lipid panel, including total, LDL and HDL cholesterol, and Tiglycerides
Time frame
Change from baseline at 3 months2
Change in markers of inflammation at 3 months
Markers of inflammation as measured by Luminex cytokine panel IL-17
Time frame
change from baseline at 3 months3
Change in gut microbiome profile at 3 months
Gut microbiome profile as measured by fecal 16S rRNA gene sequencing
Time frame
Change from baseline at 3 months4
Change in blood markers of intestinal permeability at 3 months.
Blood marker of intestinal permeability as measured by ELISA for LBP and LPS
Time frame
Change from baseline at 3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov